Gregory Verdine

Gregory L.
Verdine is the founder of Enanta Pharmaceuticals, Inc. (1995), Rein Therapeutics, Inc. (2001), Tokai Pharmaceuticals, Inc. (2004), Sesen Bio, Inc. (2008), Warp Drive Bio, Inc. (2012), Wave Life Sciences Ltd. (2012), Wave Life Sciences USA, Inc. (2012), Gloucester Marine Genomics Institute (2013), Gloucester Biotechnology Academy (2013), and LifeMine Therapeutics, Inc. (2016).
Titles held at these companies included Independent Director at Enanta Pharmaceuticals, Inc., Director at Rein Therapeutics, Inc., Director at Wave Life Sciences Ltd., Director at Wave Life Sciences USA, Inc., Director at Sesen Bio, Inc., President, Director & Chief Scientific Officer at Warp Drive Bio, Inc., Director at Gloucester Marine Genomics Institute, Director at Gloucester Biotechnology Academy, and President, Chief Executive Officer & Director at LifeMine Therapeutics, Inc. Dr. Verdine is also the founder of Gloucester Pharmaceuticals, Inc...
Current jobs include Professor at Harvard University since 1988, Professor at Harvard Medical School since 1989, and Venture Partner at 6 Dimensions Capital.
Former jobs include Director at Gates Foundation Trust, Director at Dana-Farber Cancer Institute, Inc., Director-Scientific Counsellors at National Cancer Institute, Director-Scientific Counselors at Memorial Sloan Kettering Cancer Center, Principal at Mendel Biotechnology, Inc., Venture Partner at Apple Tree Venture Management LLC from 2003 to 2009, Venture Partner at Third Rock Ventures LLC, and Venture Partner at TPG Biotech.
Education includes undergraduate studies at St. Joseph's University and a doctorate from The Trustees of Columbia University in The City of New York conferred in 1986.